Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00176839 · ClinicalTrials.gov registry record · Phase 2
Stem Cell Transplantation for Hematological Malignancies
A Phase 2 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT00176839 is a Phase 2 study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 11 participants.
The verdict
NCT00176839, a Phase 2 study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This protocol using busulfan, cyclophosphamide and melphalan has been designed as conditioning therapy for patients receiving stem cell transplantation for acute leukemia or myelodysplastic syndrome (MDS). The hypothesis is that this new regimen will be well tolerated and will cure the patient.
Interventions
- DRUG Cyclophosphamide
- DRUG Melphalan
- DRUG Busulfan
- DRUG G-CSF
- PROCEDURE Stem Cell Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2000-06-07 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00176839
The ClinicalTrials.gov registry entry for NCT00176839 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00176839 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00176839 about?
NCT00176839 is a clinical study titled "Stem Cell Transplantation for Hematological Malignancies". This protocol using busulfan, cyclophosphamide and melphalan has been designed as conditioning therapy for patients receiving stem cell transplantation for acute leukemia or myelodysplastic syndrome (MDS). The hypothesis is that this new regimen will be well tolerated and will cure the patient.
What is the current status of trial NCT00176839?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2000-06-07. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00176839?
The interventions under investigation include: Cyclophosphamide (DRUG), Melphalan (DRUG), Busulfan (DRUG), G-CSF (DRUG), Stem Cell Transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00176839?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.